<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756817</url>
  </required_header>
  <id_info>
    <org_study_id>2/27.1.2021</org_study_id>
    <nct_id>NCT04756817</nct_id>
  </id_info>
  <brief_title>Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece</brief_title>
  <acronym>GREVAXIMO</acronym>
  <official_title>Immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in Elderly People Over 85 Years of Age: Real World Data From Greece</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.Gennimatas General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G.Gennimatas General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Real-world evidence confirming the effectiveness and safety of the new COVID-19 vaccines&#xD;
      among the elderly is currently lacking. However, scarce (sparse) data derived from phase&#xD;
      II/III trials attest to a weaker humoral immune response generated post-immunization among&#xD;
      seniors, in contrast to younger adults. According to the national priority vaccination scheme&#xD;
      the age group of 85 and older was the first to receive the BNT162b2 mRNA Covid-19 vaccine in&#xD;
      Greece. The aim of the study is to enhance our insight into the humoral immunity and antibody&#xD;
      generation elicited by the BNT162b2 mRNA Covid-19 vaccine among the elderly. The study&#xD;
      population will include people aged 85 or older who are either uninfected or have a positive&#xD;
      history of PCR-confirmed SARS-CoV-2 infection occurring one to 4.5 months prior to&#xD;
      vaccination. Upon receipt of informed consent, a cohort of persons vaccinated in the two&#xD;
      vaccination centers of the &quot;G. Gennimatas&quot; General Hospital of Thessaloniki will be followed&#xD;
      over a period of six months post-injection of the second dose. To monitor the immunogenicity&#xD;
      of the BNT162b2 mRNA Covid-19 vaccine, the SARS-CoV-2 IgG II Quant assay will be applied to&#xD;
      conduct both qualitative and quantitative determination of IgGs against the receptor-binding&#xD;
      domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein on day 21 after the first&#xD;
      dose, day 21 after the second dose and within 3 and 6 months after the second dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Real world data regarding the effectiveness and safety of the new COVID-19 vaccines in older&#xD;
      people are currently lacking. The sparse data from Phase II/II trials suggest a reduction in&#xD;
      antibody responses in older people compared to younger participants. The over-85 age group&#xD;
      was the first group to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the&#xD;
      national priority vaccination scheme. The aim of the study is to enhance insight into the&#xD;
      immunity and antibody generation elicited by the BNT162b2 mRNA Covid-19 vaccine among elderly&#xD;
      people over age 85. The study population will include both uninfected vaccinated persons and&#xD;
      persons with PCR-confirmed previous SARS-CoV-2 infection occurring one to 4.5 months prior to&#xD;
      vaccination. After informed consent a cohort of persons vaccinated in the two vaccination&#xD;
      centers of the &quot;G. Gennimatas&quot; General Hospital of Thessaloniki will be followed for six&#xD;
      months post-second dose injection. The immunogenicity of the vaccine will be measured using&#xD;
      the SARS-CoV-2 IgG II Quant assay to conduct a qualitative and quantitative determination of&#xD;
      IgGs against the receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike&#xD;
      protein on day 21 after the first dose, day 21 after the second dose and within 3 and 6&#xD;
      months after the second dose.&#xD;
&#xD;
      Having set the positivity threshold of the immunoassay (50 AU/ml) as a cut-off point,&#xD;
      participants will be classified both by history of infection with SARS-CoV-2 and by SARSCoV-2&#xD;
      IgG II Quant assay outcomes. Subsequently, the IgG geometric mean concentration (GMC) and its&#xD;
      95% Confidence Interval will be calculated, based on the recorded antibody concentration&#xD;
      values. Regarding the reactogenicity of the vaccine, on the day of blood collection the&#xD;
      participants will be asked to report their experienced side effects. Of note, participants&#xD;
      are asked to officially report all unsolicited adverse drug reactions (ADRs) to the National&#xD;
      Medicines Organization via the Yellow Card scheme. The study protocol has been endorsed and&#xD;
      ethical approval was obtained by the ethics committee of the scientific council of the &quot;G.&#xD;
      Gennimatas&quot; General Hospital (protocol number:2/12.02.2021).&#xD;
&#xD;
      Regarding the reactogenicity of the vaccine, on the day of blood collection the participants&#xD;
      will be asked to report their experienced side effects. Of note, participants are asked to&#xD;
      officially report all unsolicited adverse drug reactions (ADRs) to the National Medicines&#xD;
      Organization via the Yellow Card scheme.&#xD;
&#xD;
      The study protocol was approved and ethical approval was obtained by the ethics committee of&#xD;
      the scientific council of the &quot;G. Gennimatas&quot; General Hospital (protocol&#xD;
      number:2/12.02.2021).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine</measure>
    <time_frame>21 days after the first dose</time_frame>
    <description>Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine measured using the SARS-CoV-2 IgG II Quant assay to conduct a qualitative and quantitative determination of IgGs against the receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein on day 21 after the first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19 vaccine</measure>
    <time_frame>21 days after the second dose</time_frame>
    <description>Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine measured using the SARS-CoV-2 IgG II Quant assay to conduct a qualitative and quantitative determination of IgGs against the receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein on day 21 after the second dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19</measure>
    <time_frame>3 months after the second dose</time_frame>
    <description>Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine measured using the SARS-CoV-2 IgG II Quant assay to conduct a qualitative and quantitative determination of IgGs against the receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein 3 months after the second dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19</measure>
    <time_frame>6 months after the second dose</time_frame>
    <description>Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine measured using the SARS-CoV-2 IgG II Quant assay to conduct a qualitative and quantitative determination of IgGs against the receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein 6 months after the second dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR-confirmed cases of SARS-CoV-2 infection anytime after the first dose.</measure>
    <time_frame>6 months after the second dose</time_frame>
    <description>PCR-confirmed cases of SARS-CoV-2 infection anytime after the first dose measured using hospital records</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Immunogenicity, Vaccine</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma samples retained, with no potential for DNA extraction from any retained sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly aged 85 or older prioritised for vaccination based on the greek national&#xD;
        vaccination plan&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of 85 or older&#xD;
&#xD;
          2. Without previously known SARS-CoV-2 infection, or&#xD;
&#xD;
          3. With previous PCR-confirmed SARS-CoV-2 infection one to 4.5 months prior to&#xD;
             vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Occurence of any other vaccination 4 weeks prior to enrollment&#xD;
&#xD;
          -  Participation in any other clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>85 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Georgios Papazisis, As.Professor</last_name>
    <role>Study Chair</role>
    <affiliation>School of Medicine,Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konstantina Kontopoulou, MD,PhD</last_name>
    <phone>+30 2310963179</phone>
    <email>Konstantinakontopoulou9@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>G. Gennimatas General Hospital</name>
      <address>
        <city>Thessalon√≠ki</city>
        <state>Thessaloniki</state>
        <zip>54635</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantina Kontopoulou</last_name>
      <phone>00302310963179</phone>
      <email>ntinakont@yahoo.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Georgios Papazisis</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Pharmacology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The datasets generated during and/or analysed during the current study will be available from the corresponding author on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD and any additional supporting information will become available starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Completely anonymised, de-identified (stripped of all &quot;direct identifiers&quot;) numerical data in spreadsheets will be shared with researchers from the academia and relevant research institutions after the publication of corresponding results in peer reviewed academic journals, for purposes of independent statistical analysis and verification of results. Participants will provide consent for the use of anonymised data for research purposes.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

